Review
. 2007 Oct 1;7 Spec No A(Special issue A):S77-87.
doi: 10.1102/1470-7330.2007.9008.
PET/CT in oncology: for which tumours is it the reference standard?
Affiliations
- PMID: 17921085
- PMCID: PMC2727966
- DOI: 10.1102/1470-7330.2007.9008
Item in Clipboard
Review
PET/CT in oncology: for which tumours is it the reference standard?
Cancer Imaging.
.
Abstract
Positron emission tomography (PET)/computed tomography (CT) has a growing role in the imaging of many cancers. As our experience has grown over the past number of years so has our understanding for which cancers it is particularly useful. The value of PET/CT at each stage of the cancer journey is different for each cancer. This review attempts to tease out the role of PET/CT in the common cancers with particular emphasis on where it is the imaging investigation of choice.
Similar articles
-
PET in oncology: will it replace the other modalities?Semin Nucl Med. 1997 Apr;27(2):94-106. doi: 10.1016/s0001-2998(97)80042-6. Semin Nucl Med. 1997. PMID: 9144854 Review.
-
[Positron emission tomography (PET) in clinical oncology. Part II].Rev Esp Med Nucl. 2002 Apr;21(2):131-47; quiz 149-51. doi: 10.1016/s0212-6982(02)72051-x. Rev Esp Med Nucl. 2002. PMID: 11879626 Review. Spanish. No abstract available.
-
Clinical applications of PET in oncology.Radiology. 2004 May;231(2):305-32. doi: 10.1148/radiol.2312021185. Epub 2004 Mar 24. Radiology. 2004. PMID: 15044750 Review.
-
Positron emission tomography for benign and malignant disease.Surg Clin North Am. 2011 Feb;91(1):249-66. doi: 10.1016/j.suc.2010.10.012. Surg Clin North Am. 2011. PMID: 21184913 Free PMC article. Review.
-
[Cost-effective PET investigations in oncology].Magy Onkol. 2002;46(3):203-23. Epub 2002 Oct 6. Magy Onkol. 2002. PMID: 12368917 Review. Hungarian.
Cited by
-
Combined PET/MRI: a new dimension in whole-body oncology imaging?Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S113-20. doi: 10.1007/s00259-008-0951-6. Eur J Nucl Med Mol Imaging. 2009. PMID: 19104802 Review.
-
Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions.Nucl Med Mol Imaging. 2014 Mar;48(1):26-32. doi: 10.1007/s13139-013-0240-6. Epub 2013 Oct 15. Nucl Med Mol Imaging. 2014. PMID: 24900135 Free PMC article.
-
A Comparison Study of Esophageal Findings on (18)F-FDG PET/CT and Esophagogastroduodenoscopy.Nucl Med Mol Imaging. 2016 Jun;50(2):123-9. doi: 10.1007/s13139-015-0376-7. Epub 2015 Oct 16. Nucl Med Mol Imaging. 2016. PMID: 27275360 Free PMC article.
-
Correlation Between Apparent Diffusion Coefficients and Standardized Uptake Values in Hybrid (18)F-FDG PET/MR: Preliminary Results in Rectal Cancer.Nucl Med Mol Imaging. 2016 Jun;50(2):150-6. doi: 10.1007/s13139-015-0390-9. Epub 2016 Jan 13. Nucl Med Mol Imaging. 2016. PMID: 27275364 Free PMC article.
-
The role of nuclear medicine in modern therapy of cancer.Tumour Biol. 2012 Jun;33(3):629-40. doi: 10.1007/s13277-012-0373-8. Epub 2012 Mar 24. Tumour Biol. 2012. PMID: 22446937 Review.
References
-
- von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–22. - PubMed
-
- Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–85. - PubMed
-
- Yau YY, Chan WS, Tam YM, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med. 2005;46:283–91. - PubMed
-
- Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45(Suppl 1):S56–65. - PubMed
-
- Cohade C, Osman M, Nakamoto Y, et al. Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med. 2003;44:412–16. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous